Young Adults with Violent Behavior During Early Psychosis
Launched by COLUMBIA UNIVERSITY · Feb 23, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping young adults who are experiencing early signs of psychosis and have shown violent behavior. The goal is to test a new, evidence-based approach that aims to reduce these violent behaviors in individuals aged 16 to 30 who have been diagnosed with conditions like schizophrenia or other related disorders. Participants will receive treatment at specific clinics and will be asked to take part in research interviews after each visit to help gather important information about the intervention.
To be eligible for the study, participants need to be between 16 and 30 years old and have a diagnosis of nonaffective psychosis, which means they have symptoms but do not have mood-related issues like depression. They must also be receiving care at one of the designated OnTrackNY clinics. However, individuals who cannot give informed consent or are not fluent in English will not be able to participate. This study is currently recruiting participants, and it offers a chance to contribute to important research that may help improve care for others in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria for EIS participants:
- • Ages 16 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified/unspecified schizophrenia spectrum and other psychotic disorders (International Classification of Disease Clinical Modification (ICD-10-CM) Diagnosis Code F20.x)
- • Receive First Episode Psychosis (FEP) treatment in one of OnTrackNY clinics/sites with an eligible EIS clinicians
- • Willing to participate in research interviews after each study visit during the study period
- Exclusion Criteria:
- • Unable to provide informed consent
- • Not fluent (speaking, reading, writing) in English
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Stephanie Rolin, MD, MPH
Principal Investigator
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials